Schizophrenia is a debilitating disorder that affects almost 1% of the world's population. The burden on the caregivers of patients is immense, and the cost of care in the U.S. is >$60 billion/y. Virtually all of the major antipsychotics approved y the FDA act primarily on dopamine and/or serotonin receptor function. Unfortunately, these antipsychotics produce serious side effects and are ineffective in treating negative symptoms and cognitive deficits of schizophrenia. Thus, there is an urgent need to develop treatments to alleviate these symptoms and deficits for schizophrenia patients preferably with novel drug candidates. Our long term goal is to generate compounds that are -subunit selective ligands of the GABAA receptors to determine the biological functions of different -subunits and to develop new therapies for human diseases. The objective here is to generate nonsedating agents for the treatment of negative symptoms and cognitive deficits of schizophrenia with little or no abuse potential (weak or no efficacy at 1 GABAA receptor subunits). Our central hypothesis is that selective modulators of the ?3,?5, or ligands with equal efficacy for the ?2,?3, and ?5 subunits (?2/?3/?5) bearing GABAA receptors, which have been shown to attenuate negative symptoms and cognitive deficits of schizophrenia in animal models of this disease, are potentially the first drug candidates to address these symptoms of schizophrenia. The rationale is that these drug candidates will be available for IND filing and clinical trials once the development of current lea compounds described in this application is successfully completed. The following four specific aims are proposed: 1) Determine the activity of selective GABAA receptor modulators in animal models of schizophrenia;2) Develop highly ?5 and ?2/?3/?5 selective GABAA receptor modulators;3) Develop highly 3 selective GABAA receptor modulators;and 4) Determine in vivo activity of highly subtype selective GABAA receptor modulators.
Under specific aim one two lead compounds successfully re- versed the increase of tonic DA transmission in MAM rats, which suggests that these compounds would be effective in alleviating DA-mediated psychosis. Additionally, behavioral sensitivity to psychostimulants was reduced, restoring the rhythmicity within HPC-efferent structure, which is expected to be important for the alleviation of cognitive and negative symptoms of schizophrenia. Additionally, these compounds were able to reverse the cognitive symptoms of schizophrenia in the PPI model of PCP treated rats but induced no signs of catalepsy.
Under specific aims 2 and 3, synthetic routes to generate the proposed compounds are already establish and under specific aims 4 nonsedating properties of lead compounds has been evaluated in different animal models including rhesus monkeys. The approach is innovative because it focuses on the development and application of chiral and -subtype selective imidazobenzodiazepines (IBZ) as new therapies for schizophrenia. The proposed work is significant because it represents the first step in a continuum of research to develop the first therapies for impaired cognitive function and negative symptoms of schizophrenia patients.
The proposed research is relevant to public health because the development of alpha subtype selective GABAA receptor ligands is ultimately expected to increase our understanding of the central nervous system and enables the development of new drugs to treat mental disorders and diseases. The proposed research is relevant to the part of NIH's mission to apply fundamental knowledge to reduce the devastating burden on the families and caregivers of schizophrenia patients.
|Namjoshi, Ojas A; Cook, James M (2016) Sarpagine and Related Alkaloids. Alkaloids Chem Biol 76:63-169|
|StameniÄ‡, Tamara TimiÄ‡; Poe, Michael M; Rehman, Sabah et al. (2016) Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the Î±5 subunit. Eur J Pharmacol 791:433-443|
|Piantadosi, Sean C; French, Beverly J; Poe, Michael M et al. (2016) Sex-Dependent Anti-Stress Effect of an Î±5 Subunit Containing GABAA Receptor Positive Allosteric Modulator. Front Pharmacol 7:446|
|Forkuo, Gloria S; Guthrie, Margaret L; Yuan, Nina Y et al. (2016) Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments. Mol Pharm 13:2026-38|
|Jonas, Oliver; Calligaris, David; Methuku, Kashi Reddy et al. (2016) First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol 12:1297-302|
|Yuan, Nina Y; Poe, Michael M; Witzigmann, Christopher et al. (2016) Characterization of GABAA receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. J Pharmacol Toxicol Methods 82:109-114|
|Fischer, Bradford D; Platt, Donna M; Rallapalli, Sundari K et al. (2016) Antagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis. Drug Alcohol Depend 158:22-9|
|TimiÄ‡ StameniÄ‡, Tamara; JoksimoviÄ‡, Srdjan; Biawat, Poonam et al. (2015) Negative modulation of Î±â‚… GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. J Psychopharmacol 29:1013-24|
|O'Tousa, David S; Warnock, Kaitlin T; Matson, Liana M et al. (2015) Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice. Addict Biol 20:236-47|
|Gallos, George; Yocum, Gene T; Siviski, Matthew E et al. (2015) Selective targeting of the Î±5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling. Am J Physiol Lung Cell Mol Physiol 308:L931-42|
Showing the most recent 10 out of 51 publications